Provided by Tiger Trade Technology Pte. Ltd.

Day One Biopharmaceuticals Inc.

10.65
-0.2800-2.56%
Pre-market: 10.50-0.1538-1.44%08:44 EST
Volume:2.55M
Turnover:27.04M
Market Cap:1.10B
PE:-7.22
High:10.91
Open:10.91
Low:10.33
Close:10.93
52wk High:13.20
52wk Low:5.64
Shares:103.30M
Float Shares:78.77M
Volume Ratio:1.16
T/O Rate:3.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4748
EPS(LYR):-1.0243
ROE:-22.74%
ROA:-14.64%
PB:2.49
PE(LYR):-10.40

Loading ...

Wedbush Adjusts Price Target on Day One Biopharmaceuticals to $29 From $25, Maintains Outperform Rating

MT Newswires Live
·
Nov 14, 2025

Day One Biopharmaceuticals Inc : Piper Sandler Cuts Target Price to $25 From $26

THOMSON REUTERS
·
Nov 14, 2025

Analysts Conflicted on These Healthcare Names: Bioxcel Therapeutics (BTAI) and Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
Nov 13, 2025

Oppenheimer says Day One paying up to $285M for Mersana ‘is interesting’

TIPRANKS
·
Nov 13, 2025

Day One Biopharmaceuticals Announces Mersana Acquisition Deal

TIPRANKS
·
Nov 13, 2025

Day One to Buy Mersana Therapeutics for Up to $285 Million

Dow Jones
·
Nov 13, 2025

Mersana Therapeutics Inc Proposed Deal for $25.00 per Share in Cash

THOMSON REUTERS
·
Nov 13, 2025

Mersana Therapeutics Inc - Day One to Buy Mersana for up to $285 Mln

THOMSON REUTERS
·
Nov 13, 2025

Stock Track | Day One Biopharmaceuticals Soars 5% on Promising OJEMDA Data for Pediatric Brain Cancer

Stock Track
·
Nov 10, 2025

Stock Track | Day One Biopharmaceuticals Soars 5.04% on Promising OJEMDA™ Trial Results for Pediatric Brain Cancer

Stock Track
·
Nov 10, 2025

Day One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial

Reuters
·
Nov 10, 2025

Day One Announces New Ojemda™ (Tovorafenib) Data to Be Presented in Oral Session at the 2025 Society for Neuro-Oncology (Sno) Annual Meeting

THOMSON REUTERS
·
Nov 10, 2025

A NEW DAWN OF HOLISTIC WELLNESS AT THE RITZ-CARLTON SPA SINGAPORE: REDEFINING LUXURY WITH THE FUTURE OF SKINCARE

prnewswire
·
Nov 06, 2025

Day One Biopharmaceuticals Up Nearly 26%, on Pace for Largest Percent Increase Since June 2022 -- Data Talk

Dow Jones
·
Nov 06, 2025

Analysts’ Opinions Are Mixed on These Healthcare Stocks: PROCEPT BioRobotics (PRCT), Day One Biopharmaceuticals (DAWN) and Exelixis (EXEL)

TIPRANKS
·
Nov 06, 2025

Day One Biopharm Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Nov 05, 2025

Stock Track | Day One Biopharmaceuticals (DAWN) Soars 8.29% on Strong Q3 Results and Analyst Endorsement

Stock Track
·
Nov 05, 2025

Stock Track | Day One Biopharmaceuticals (DAWN) Soars 6.30% Pre-market on Strong Q3 Results and Analyst Upgrade

Stock Track
·
Nov 05, 2025

Stock Track | Day One Biopharmaceuticals (DAWN) Surges 6.30% Pre-market on Strong Q3 Results and Analyst Endorsement

Stock Track
·
Nov 05, 2025

H.C. Wainwright Sticks to Their Buy Rating for Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
Nov 05, 2025